Quantinno Capital Management LP Acquires Shares of 146,938 Certara, Inc. (NASDAQ:CERT)

Quantinno Capital Management LP purchased a new stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 146,938 shares of the company's stock, valued at approximately $1,565,000. Quantinno Capital Management LP owned approximately 0.09% of Certara as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently modified their holdings of the company. Principal Financial Group Inc. grew its holdings in Certara by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 531,445 shares of the company's stock worth $5,660,000 after acquiring an additional 15,739 shares in the last quarter. First Trust Advisors LP bought a new position in shares of Certara during the fourth quarter valued at approximately $140,000. Vontobel Holding Ltd. purchased a new position in Certara during the fourth quarter valued at approximately $1,295,000. Raymond James Financial Inc. purchased a new position in Certara during the fourth quarter valued at approximately $3,628,000. Finally, Proficio Capital Partners LLC bought a new position in Certara in the fourth quarter worth approximately $148,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Stock Performance

CERT stock traded down $0.11 during trading on Wednesday, reaching $11.44. The company had a trading volume of 153,152 shares, compared to its average volume of 1,327,456. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -57.23, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. Certara, Inc. has a twelve month low of $8.64 and a twelve month high of $17.76. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm has a 50-day simple moving average of $11.82 and a 200-day simple moving average of $11.78.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $106.00 million for the quarter, compared to analyst estimates of $104.44 million. During the same period in the previous year, the company earned $0.10 earnings per share. The business's quarterly revenue was up 9.7% compared to the same quarter last year. As a group, sell-side analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Robert W. Baird lifted their price target on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Stephens reiterated an "overweight" rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th. KeyCorp increased their price target on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. William Blair reaffirmed a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Finally, TD Cowen started coverage on shares of Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Certara currently has an average rating of "Moderate Buy" and an average price target of $15.67.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.